Ma passion est de promouvoir la prestation de services d’excellente qualité dans tous les foyers du Nouveau-Brunswick. Vers la fin de l’été 2019, j’ai également fait partie du groupe de travail qui a été formé pour restructurer les normes et règlements des foyers de soins spéciaux. J’étais secrétaire de la New Brunswick Special Care Home Association depuis six ans. Je dirige notre entreprise familiale depuis 20 ans et j’ai été technicienne en pharmacie pendant sept ans. I believe change is needed in out sector and I’m ecstatic to be part of it! My passion is to advocate for excellent quality services be provided in all homes in New Brunswick. In the late summer of 2019, I was also part of the working group that was created to restructure the Special Care home Standards and Regulations. I've been the Secretary of the New Brunswick Special Care Home Association for the last 6 years. They also showed low technical variability of single cell sequencing analysis among various clinical centers demonstrating the feasibility of using single cell sequencing in multicenter trials in the future.I’ve been operating our family business for that last 20 years and was a pharmacy technician for seven years. O Enriched communication of BAFF and CCL signaling pathways in T and myeloid cells. Danielle Gallant Guardian Realty 4.5 9 Reviews 5 sales in the last 12 months About me Broker/Principal ( 11 year s experience) Specialties Buyer's agent Listing agent Consulting Property Management As the Broker of Guardian Realty I value each and every customer. O Rnrichment of IFN-ɣ and IFN-δ downstream targets in myeloid cells O Decreased expression of cytolytic markers The authors characterized the immune microenvironment modifications associated with rapid progressors among multiple myeloma patients such as: This recent study shows how #singlecell #sequencing can leverage new findings about the #tumormicroenvironment in multiple myeloma in the context of multicenter clinical trials: It’s an exciting time for #multiplemyeloma research. #MultipleMyeloma #cartcelltherapy #NovelApproach #ClinicalTrials #Treatment #CancerResearch #Oncology #MedicalAdvancements This comprehensive review highlights the development and outcomes of CAR T-cell therapy in MM, the limitations and toxicities associated with the therapy, and the strategies being pursued to overcome therapeutic challenges in the pursuit of a cure for MM.Īs a rapidly evolving field, CAR T-cell therapy in MM represents a crucial area of study for oncologists and researchers alike.īy highlighting the current state of the field and areas for further investigation, this review provides valuable insights into the future of CAR T-cell therapy in the treatment of MM. In light of this unmet medical need, the development of chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising approach for the treatment of relapsed, refractory MM (RRMM).ĬAR T-cell therapy involves the genetic modification of cellular therapies, which have shown significant efficacy in achieving deep and durable remissions in other B-cell malignancies.Įarly studies of CAR T-cell therapy in RRMM have demonstrated remarkable response rates, however, long-term durability remains an area of ongoing research. Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of transformed plasma cells.ĭespite significant progress in MM treatment, a cure remains elusive for the majority of patients, especially those with triple-class refractory MM who have developed resistance to immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies. Shane Swatts Miguel López de Silanes Gómez Carmelo Chines Fabrizio Chines Benoit COLLET Nick Atkins Rachna Murthy Jonathan Roos Alessandro Moroni Yvonne Hernández González Rick Good Samer Hamada Dr. FAAO Christopher Starr Benjamin Sullivan John Gelles Yang Liu Sabrina Zappia Dr. #TFOSLifestyle #eyesarethestory #ocularsurfacedisease #dryeye #eyecare #cosmetics #scienceofeyes #teamwork #optocosmetics Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, Dipl ABO Leslie O'Dell, O.D. Look forward to sharing more of “The Story” around the world! Key takeaway: Education is paramount (and too many female ophthalmologists & patients in the Middle East apply eyeliner to their waterline!) Lazreg Sihem from Algeria and discussed how we can better educate clinicians and patients worldwide on eye-safe cosmetics. And, very proud of Dad who gave the Keynote and received an award and recognition for his global achievements. Great honor to be on stage with my father, David Sullivan, and Stefano Barabino from Milano. Whirlwind visit to Abu Dhabi to present at the 20th Emirates Society of Ophthalmology Conference - about how cosmetics impact the ocular surface.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |